Ushio is excited to share news regarding a Far UV-C clinical trial currently underway in Canada. Research NovaScotia is conducting a $2.8M study at three long-term care facilities in NovaScotia with the support of Ushio’s Care222 partner, UVX. This randomized double-blind placebo control trial is the first of its kind using filtered Far UV-C globally. Among other objectives, the clinical trial will investigate skin safety, eye safety, and effectiveness of Far UV-C in mitigating infection rates of high-risk senior care residents.
Read Full Article